Biochemical and pharmacological properties of SANORG 32701: Comparison with the 'synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin

Circulation Research

Volumn 79, Issue 3, 1996, Pages 590-600

  Herbert, J M ^a   Herault J P ^a   Bernat, A ^a   Van Amsterdam, R G M ^b   Vogel, G M T ^b   Lormeau, J C ^a   Petitou, M ^a   Meuleman, D G ^b  

^a SANOFI   (France)

^b NV ORGANON   (Netherlands)

Author keywords

factor Xa; pentasaccharide; SANORG 32701; thrombosis

Indexed keywords

FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; PENTASACCHARIDE; SANORG 32701; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

EID: 0029794151     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.79.3.590     Document Type: Article

References (38)

1. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs. 1990;40:498-530.
2. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs. 1995;49:856-884.
3. Paques EP, Römisch J. Comparative study on the in vivo effectiveness of antithrombotic agents. Thromb Res. 1991;64:11-21.
4. Berry C, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost. 1994;72:381-386.
5. Freund M, Cazenave JP, Courtney M, Degryse E, Roitsch C, Bernat A, Delebassee D, Defreyn G, Maffrand JP. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemost. 1990;63:187-192.
6. Agnelli G, Pascucci C, Cosni B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost. 1990;63:204-207.
7. Van Boeckel CAA, Petitou M. The unique antithrombin binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Ind (Ed Engl). 1993;32:1671-1690.
8. Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost. 1989;61:397-401.
9. Vogel GM, Meuleman DG, Bourgondiën FG, Hobbelen M. Comparison of two experimental thrombosis models in rats: effect of four glycosaminoglycans. Thromb Res. 1989;54:399-410.
10. Hobbelen PMJ, Van Dinther TG, Vogel GMT, Van Boeckel CAA, Moelker HCT, Meuleman DG. Pharmacological profile of the chemically synthetized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost. 1990;63:265-272.
11. Walenga JM, Farced J, Petitou M, Samama M, Lormeau JC, Choay J. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb Res. 1986;43:243-248.
12. Walenga JM, Petitou M, Lormeau JC, Samama M, Farced J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res. 1987;46:187-198.
13. Walenga JM, Petitou M, Samama M, Farced J, Choay J. Importance of a 3-O-sulphate group in a heparin pentasaccharide for antithrombotic activity. Thromb Res. 1988;52:553-563.
14. Cadroy Y, Hansson SR, Harker LA. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost. 1993;70:631-635.
15. Boneu B, Necciari J, Magnani H, Kieffer G, Mant T, Morrison P, Singer B, Lamond G, Dickinson J. Pharmacokinetics of the natural pentasaccharide (SR 90107/ORG 31540) with high affinity for antithrombin III following subcutaneous administration in man. Thromb Haemost. 1993;69:406. Abstract.
16. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1978;13:285-288.
17. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost. 1986;56:9-17.
18. Lormeau JC, Herault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide. Thromb Haemost. 1993;69:152-156, 176.
19. Mc Kay EJ. A simple two-step procedure for the isolation of antithrombin III from biologicals fluids. Thromb Res. 1981;21:375-382.
20. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry. 1987;26:6454-6461.
21. Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin and factor Xa to the amithrombotic effect of heparin. Blood. 1985;65:198-201.
22. Boneu B, Buchanan MR, Cade JF, Van Ryn, Fernandez FF, Ofosu FA, Hirsh J. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res. 1985;40:81-89.
23. Hladovec I. Experimental arterial thrombosis in rats with continuous registration. Thromb Diathes Haemorrh. 1971;26:407-410.
24. Umetsu T, Sanai K. Effect of KC-6141, an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemost. 1978; 39:74-83.
25. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest. 1983;71:368-376.
26. Van Amsterdam RGM, Vogel GMT, Visser A, Kop WJ, Buiting MT, Meuleman DG. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin: prediction of the in vivo residence times. Arterioscler Thromb Vase Biol. 1995;15:495-503.
27. Maffrand JP. Direct thrombin inhibitors. Nouv Rev Fr Hematol. 1992;34:405-419.
28. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. J Biol Chem. 1992;267:12528-12538.
29. Choay J, Petitou M, Lormeau JC, Sinay P, Casu BJ, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983;116:492-499.
30. Masys DR, Bajaj SP, Rapaport SI. Activation of human factor VII by activated factors IX and X. Blood. 1982;60:1143-1150.
31. Lormeau JC, Herault JP, Herbert JM. The synthetic pentasaccharide representing the heparin binding site to antithrombin III inhibits factor VIIa-tissue factor complex. Thromb Haemost. In press.
32. Carrie D, Caranobe C, Saivin S, Houin G, Petitou M, Lormeau JC, Van Boeckel C, Meuleman D, Boneu B. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY 216. Blood. 1994;84:2571-2577.
33. Eisenberg PR, Jeffrey ES, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993;91:1877-1883.
34. Vogel GMT, van Amsterdam RGM, Kop WJ, Meuleman DG. Pentasaccharide and Orgaran™ arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost. 1993;69:29-34.
35. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation. 1995;92:962-967.
36. Just M, Tripier D, Seiffge D. Antithrombotic effects of recombinant hirudin in different animal models. Haemostasis. 1991;21:80-87.
37. Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RF, Tweed MF, Wallis RB. Recombinant desulphatohirudin (CGP 39393): anticoagulant and antithrombotic properties in vivo. Thromb Haemost. 1989;61:77-80.
38. Jackson CV, Crowe G, Frank JD, Wilson HC, Coffman WJ, Utter-back BG, Jakubowshi JA, Smith GF. Pharmacological assessment of antithrombotic activity of the peptide inhibitor, D-methyl-phenyl-alanyl-prolyl-arginyl (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 1992;261:546-552.